Technology
Engineered to
redefine toxins
Recombinant Botulinum Neurotoxin
A recombinant botulinum toxin platform engineered through a 2-part production method for faster and safer development.
Recombinant BoNT(rBoNT)
Conventional botulinum toxin(BoNT) products could only be produced from naturally occurring strains of Clostridium botulinum, which posed significant limitations. MVRIX uses E. coli as the host strain to produce the toxin, overcoming these constraints and unlocking new possibilities for botulinum therapeutics.
Conventional BoNT
Difficult to
find in nature
Difficult to secure diverse strains
Difficult to
engineer strains
Conventional botulinum toxin products are produced only from naturally occurring strains of Clostridium botulinum. However, such strains are extremely rare in nature, and securing diverse types suitable for pharmaceutical use remains an even greater challenge.
Recombinant BoNT
Feasible for laboratory production
Capable of
producing multiple types by domain
Flexible
engineering
Recombinant botulinum toxin is produced in E. coli as separate fragments, making the process highly safe while also allowing selective production of desired domains and properties.
Advantages
Core toxins resistant to immunity
Core toxins can be produced quickly and safely without inducing resistance.
Improved botulinum toxins
Botulinum toxins can be developed with faster onset and longer duration of action.
Domain engineering
By engineering different domains of botulinum toxins, their indications can be expanded.
Improved
Production system
-
We use E. coli as the host to eliminate the risk of strain disputes and to produce core toxins with a very low likelihood of resistance.
-
Through a 2-part production method, we have improved process safety and maximized efficiency by shortening production time.
Broader Application
Various serotypes can be produced in E. coli, and with our engineering techniques, they can be adapted to a wide range of indications, from aesthetic use to medical applications.
Botulinum toxin consists of three core domains: LC, Hn, and Hc.
R&D Achievements
Discover the intellectual property activities we are pursuing around rBoNT.
Filed
IN
2/21/22
Filed
보툴리눔 신경 독소의 안전한 제조 방법
Filed
EU
2/22/22
Filed
보툴리눔 신경 독소의 안전한 제조 방법
Filed
KR
3/7/24
Filed
가용화 파트너 및 인테인을 이용한 보툴리눔 독소 생산방법
Filed
KR
10/24/24
Filed
FGF 단백질과 BoNT 단백질이 융합된 FGF-BoNT 융합단백질 및 이를 함유하는 화장료 조성물
10-2547393
KR
6/20/23
Granted
보툴리늄 독소 전위 도메인 및 엔도라이신을 포함하는 단백질 복합체 및 이를 포함하는 항균 조성물
10-2597062
KR
10/27/23
Granted
3분할 단편 생산을 이용한 보툴리눔 신경 독소의 안전한 생산 방법
10-2610179
KR
11/30/23
Granted
보툴리눔 신경 독소의 안전한 제조 방법
ZL 202080059073.1
CN
8/6/24
Granted
보툴리눔 신경 독소의 안전한 제조 방법
10-2731131
KR
11/12/24
Granted
가용화 파트너 및 GP41.1 인테인을 이용한 보툴리눔 독소 생산방법
12,171,815
US
12/24/24
Granted
보툴리눔 신경 독소의 안전한 제조 방법
12,171,814
US
12/24/24
Granted
보툴리늄 독소 전위 도메인 및 엔도라이신을 포함하는 단백질 복합체 및 이를 포함하는 항균 조성물
10-2790255
KR
3/28/25
Granted
재조합 보툴리눔 독소 및 이를 함유하는 약학 조성물
출원
PCT
12/17/20
출원
보툴리눔 신경 독소의 안전한 제조 방법
출원
PCT
4/17/22
출원
보툴리눔 독소 전위 도메인 및 엔도라이신을 포함하는 단백질 복합체 및 이를 포함하는 항균 조성물
출원
PCT
3/6/25
출원
수용성 파트너 및 인테인을 이용한 보툴리눔 독소 생산방법